Comparative Pharmacology
Head-to-head clinical analysis: INGREZZA versus INGREZZA SPRINKLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INGREZZA versus INGREZZA SPRINKLE.
INGREZZA vs INGREZZA SPRINKLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vesicular monoamine transporter 2 (VMAT2) inhibitor; reduces presynaptic dopamine release.
INGREZZA SPRINKLE contains valbenazine, a selective VMAT2 inhibitor that reduces the release of dopamine into the synaptic cleft, thereby decreasing dopaminergic neurotransmission in the striatum. The exact mechanism for the treatment of tardive dyskinesia is unknown but is thought to involve modulation of dopamine signaling.
80 mg orally once daily; may titrate from 40 mg once daily for 7 days to reduce nausea.
Initial dose: 40 mg orally once daily (as 1 capsule of INGREZZA SPRINKLE 40 mg or 4 capsules of 10 mg). After 1 week, increase to target dose of 80 mg orally once daily (as 2 capsules of 40 mg or 8 capsules of 10 mg). Capsules may be swallowed whole or opened and sprinkled onto soft food.
None Documented
None Documented
Terminal elimination half-life of deutetrabenazine is 9-10 hours; clinical context: supports twice-daily dosing.
17-20 hours; steady state reached in approximately 5 days.
Approximately 60% renal (as unchanged drug and metabolites) and 30% fecal.
60% renal (as unchanged drug and metabolites), 40% fecal (as metabolites).
Category C
Category C
VMAT2 Inhibitor
VMAT2 Inhibitor